Fortress Biotech, Inc.
FBIO
$2.72
$0.010.37%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 18.86% | 21.17% | 13.78% | 16.38% | 0.76% |
| Total Other Revenue | -37.39% | -- | -98.70% | -- | -- |
| Total Revenue | 14.04% | 22.06% | 6.34% | 20.52% | 10.18% |
| Cost of Revenue | -46.82% | -22.57% | -65.30% | -57.15% | -28.99% |
| Gross Profit | 251.55% | 110.38% | 2,101.20% | 1,538.76% | 195.60% |
| SG&A Expenses | -46.31% | -38.07% | -45.17% | -20.82% | 86.13% |
| Depreciation & Amortization | -8.93% | 5.73% | 8.56% | 30.71% | 30.71% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -45.69% | -32.94% | -44.96% | -33.44% | 32.10% |
| Operating Income | 72.57% | 65.32% | 78.99% | 69.17% | -45.09% |
| Income Before Tax | 107.91% | 676.30% | 76.08% | 133.25% | 59.57% |
| Income Tax Expenses | -- | -- | -342.86% | -62.32% | -- |
| Earnings from Continuing Operations | 105.17% | 655.51% | 79.49% | 133.07% | 59.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -103.94% | -289.90% | -92.53% | -121.53% | 51.82% |
| Net Income | -103.02% | 1,142.83% | 41.80% | 145.47% | 241.45% |
| EBIT | 72.57% | 65.32% | 78.99% | 69.17% | -45.09% |
| EBITDA | 74.68% | 69.14% | 83.24% | 73.25% | -47.47% |
| EPS Basic | -115.68% | 814.73% | 45.03% | 117.67% | 168.22% |
| Normalized Basic EPS | -115.83% | 4,032.73% | -151.80% | 1,605.48% | 30.43% |
| EPS Diluted | -117.78% | 686.64% | 45.03% | 114.41% | 161.64% |
| Normalized Diluted EPS | -117.57% | 3,329.14% | -151.80% | 1,339.38% | 17.51% |
| Average Basic Shares Outstanding | 18.27% | 19.25% | 16.80% | 38.32% | 46.75% |
| Average Diluted Shares Outstanding | 6.60% | 45.23% | 16.80% | 68.05% | 62.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |